UBS considers the valuation to be attractive and highlights the improved momentum.

The analyst confirms his buy recommendation on the stock, but lowers his price target to E172 (from E208), which represents a potential gain of 21% on the current price.

' We see the current valuation as an attractive entry point for a leading bioprocessing platform' says UBS.

'We remain disciplined and on track to achieve not only our 2023 targets, but also our medium-term targets. In 2024, we expect to return to organic sales growth', said CEO Belén Garijo.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.